Nat Biotechnol:新型3D疫苗横扫癌症及艾滋病

2014-12-10 何嫱 生物通

癌症如此致命的一个原因是它可以逃避机体免疫系统的攻击,使得肿瘤能够旺盛生长及扩散。科学家们一直在设法尝试利用免疫疗法来诱导免疫系统进入到抗癌攻击模式,建立起对癌细胞的长期免疫抵抗。 现在,来自Wyss生物启发工程研究所和哈佛大学工程与应用科学学院的研究人员证实,非手术注射可在体内自发组装成3D结构的一些可编程生物材料,可以对抗甚至帮助预防癌症以及诸如艾滋病一类的传染病。他们的研究结果发表在《自然

癌症如此致命的一个原因是它可以逃避机体免疫系统的攻击,使得肿瘤能够旺盛生长及扩散。科学家们一直在设法尝试利用免疫疗法来诱导免疫系统进入到抗癌攻击模式,建立起对癌细胞的长期免疫抵抗。

现在,来自Wyss生物启发工程研究所和哈佛大学工程与应用科学学院的研究人员证实,非手术注射可在体内自发组装成3D结构的一些可编程生物材料,可以对抗甚至帮助预防癌症以及诸如艾滋病一类的传染病。他们的研究结果发表在《自然生物技术》(Nature Biotechnology)杂志上。

研究的资深作者、Wyss研究所核心成员、哈佛大学工程与应用科学学院生物工程教授David Mooney博士说:“我们可以构建出一些3D结构,通过微创传送来富集和激活宿主的免疫细胞,在体内靶向和攻击有害细胞。”

研究人员将这些由二氧化硅制成的、可生物降解的微小杆状结构命名为介孔二氧化硅棒(mesoporous silica rods, MSRs)。MSRs可以装载一些生物和化学药物成分,通过注射传送到皮肤下。这些介孔二氧化硅棒会在接种部位自发形成一种三维支架,就像一盒火柴在桌上堆成一堆那样。MSRs堆中的多孔空隙非常的大,以致可以招募和填充树突状细胞。树突状细胞是一种负责监视人体的重要免疫细胞,当检测到有害物存在时其会触发免疫反应。

共同主要作者、Wyss研究所前博士后研究人员、韩国成均馆大学化学工程系助理教授Jaeyun Kim博士说:“研究人员曾构建出一些纳米尺寸的介孔二氧化硅颗粒用于从内部操控单个细胞,但这是第一次采用微米大小的较大颗粒在体内构建出一种3D支架,其可以招募和吸引数百万计的免疫细胞。”

在实验室中合成的这些MSRs内部具有一些称作为纳米孔(nanopore)的小孔。纳米孔中可以填充特异的细胞因子、寡核苷酸、大蛋白抗原,或是任何种类的关注药物,允许以大量可能的组合来治疗广泛的感染。

论文的共同主要作者、哈佛大学工程与应用科学学院研究生Aileen Li说:“尽管现在我们的重点是开发一种癌症疫苗,在未来我们可能能够通过利用MSRs释放不同种类的细胞因子,操控将哪种类型的树突状细胞或其他类型的免疫细胞招募到这一3D支架中。通过调整MSRs的表面特性和孔的大小,由此控制导入和释放各种蛋白质及药物,我们可以操控免疫系统来治疗多种疾病。”

一旦这一3D支架招募到来自机体的树突状细胞,MSRs中包含的药物就会被释放出来,松开它们的“监督”触发器,启动免疫反应。激活的树突状细胞会离开支架,移行到淋巴结,在那里它们发出警报,指挥机体免疫系统攻击如癌细胞等特异细胞。在数月内注射部位的MSRs会自然地发生生物降解及分解。

尽管迄今为止研究人员还只在小鼠中测试了这一3D疫苗,却发现它非常高效。一项实验表明,这些可注射3D支架在宿主小鼠体内招募和吸引了数百万计的树突状细胞,然后这些细胞分散到淋巴结,触发了强有力的免疫反应。

这些疫苗的制造容易且快速,因此当面对一种新兴传染病时它们有可能能够非常快速且广泛地得到应用。“我们预计这些3D疫苗能够广泛应用于许多情况下,它们的可注射特性使得易于在诊所内外给药,”Mooney说。

由于这些疫苗是通过触发免疫反应来起作用,这种方法可用于在感染之前通过建立机体的免疫抵抗来预防疾病。

Wyss 研究所创始主任Donald Ingber 博士说:“利用可编程生物材料,这种可注射免疫疗法是传送靶向治疗一种强大的工具,且预防保健可以帮助对抗一系列的致死性感染,包括全球的常见杀手如HIV和埃博拉病毒以及癌症。这些可注射3 D疫苗提供了一种微创且可扩展的方式来传送治疗,在以往逃避免疫检测的一些疾病中通过模拟机体自身的强大免疫反应来起作用。”

原始出处

Kim J1, Li WA2, Choi Y3, Lewin SA4, Verbeke CS2, Dranoff G5, Mooney DJ2.Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy.Nat Biotechnol. 2014 Dec 8

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1927616, encodeId=529f192e616c5, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Sep 02 00:29:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778598, encodeId=bde31e78598dd, content=<a href='/topic/show?id=1c73125078' target=_blank style='color:#2F92EE;'>#3D疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1250, encryptionId=1c73125078, topicName=3D疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Fri Mar 13 00:29:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917104, encodeId=64f2191e104ab, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Sep 22 17:29:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880409, encodeId=d14b188040954, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 15 20:29:00 CST 2015, time=2015-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652117, encodeId=1ea9165211e35, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Nov 05 10:29:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335850, encodeId=3d03133585000, content=<a href='/topic/show?id=792612047e' target=_blank style='color:#2F92EE;'>#3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1204, encryptionId=792612047e, topicName=3D)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Fri Dec 12 01:29:00 CST 2014, time=2014-12-12, status=1, ipAttribution=)]
    2015-09-02 cathymary
  2. [GetPortalCommentsPageByObjectIdResponse(id=1927616, encodeId=529f192e616c5, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Sep 02 00:29:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778598, encodeId=bde31e78598dd, content=<a href='/topic/show?id=1c73125078' target=_blank style='color:#2F92EE;'>#3D疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1250, encryptionId=1c73125078, topicName=3D疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Fri Mar 13 00:29:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917104, encodeId=64f2191e104ab, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Sep 22 17:29:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880409, encodeId=d14b188040954, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 15 20:29:00 CST 2015, time=2015-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652117, encodeId=1ea9165211e35, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Nov 05 10:29:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335850, encodeId=3d03133585000, content=<a href='/topic/show?id=792612047e' target=_blank style='color:#2F92EE;'>#3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1204, encryptionId=792612047e, topicName=3D)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Fri Dec 12 01:29:00 CST 2014, time=2014-12-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1927616, encodeId=529f192e616c5, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Sep 02 00:29:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778598, encodeId=bde31e78598dd, content=<a href='/topic/show?id=1c73125078' target=_blank style='color:#2F92EE;'>#3D疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1250, encryptionId=1c73125078, topicName=3D疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Fri Mar 13 00:29:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917104, encodeId=64f2191e104ab, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Sep 22 17:29:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880409, encodeId=d14b188040954, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 15 20:29:00 CST 2015, time=2015-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652117, encodeId=1ea9165211e35, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Nov 05 10:29:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335850, encodeId=3d03133585000, content=<a href='/topic/show?id=792612047e' target=_blank style='color:#2F92EE;'>#3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1204, encryptionId=792612047e, topicName=3D)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Fri Dec 12 01:29:00 CST 2014, time=2014-12-12, status=1, ipAttribution=)]
    2015-09-22 智慧医人
  4. [GetPortalCommentsPageByObjectIdResponse(id=1927616, encodeId=529f192e616c5, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Sep 02 00:29:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778598, encodeId=bde31e78598dd, content=<a href='/topic/show?id=1c73125078' target=_blank style='color:#2F92EE;'>#3D疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1250, encryptionId=1c73125078, topicName=3D疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Fri Mar 13 00:29:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917104, encodeId=64f2191e104ab, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Sep 22 17:29:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880409, encodeId=d14b188040954, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 15 20:29:00 CST 2015, time=2015-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652117, encodeId=1ea9165211e35, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Nov 05 10:29:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335850, encodeId=3d03133585000, content=<a href='/topic/show?id=792612047e' target=_blank style='color:#2F92EE;'>#3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1204, encryptionId=792612047e, topicName=3D)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Fri Dec 12 01:29:00 CST 2014, time=2014-12-12, status=1, ipAttribution=)]
    2015-04-15 liye789132251
  5. [GetPortalCommentsPageByObjectIdResponse(id=1927616, encodeId=529f192e616c5, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Sep 02 00:29:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778598, encodeId=bde31e78598dd, content=<a href='/topic/show?id=1c73125078' target=_blank style='color:#2F92EE;'>#3D疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1250, encryptionId=1c73125078, topicName=3D疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Fri Mar 13 00:29:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917104, encodeId=64f2191e104ab, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Sep 22 17:29:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880409, encodeId=d14b188040954, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 15 20:29:00 CST 2015, time=2015-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652117, encodeId=1ea9165211e35, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Nov 05 10:29:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335850, encodeId=3d03133585000, content=<a href='/topic/show?id=792612047e' target=_blank style='color:#2F92EE;'>#3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1204, encryptionId=792612047e, topicName=3D)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Fri Dec 12 01:29:00 CST 2014, time=2014-12-12, status=1, ipAttribution=)]
    2015-11-05 shock_melon
  6. [GetPortalCommentsPageByObjectIdResponse(id=1927616, encodeId=529f192e616c5, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Sep 02 00:29:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778598, encodeId=bde31e78598dd, content=<a href='/topic/show?id=1c73125078' target=_blank style='color:#2F92EE;'>#3D疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1250, encryptionId=1c73125078, topicName=3D疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Fri Mar 13 00:29:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917104, encodeId=64f2191e104ab, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Sep 22 17:29:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880409, encodeId=d14b188040954, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 15 20:29:00 CST 2015, time=2015-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652117, encodeId=1ea9165211e35, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Nov 05 10:29:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335850, encodeId=3d03133585000, content=<a href='/topic/show?id=792612047e' target=_blank style='color:#2F92EE;'>#3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1204, encryptionId=792612047e, topicName=3D)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Fri Dec 12 01:29:00 CST 2014, time=2014-12-12, status=1, ipAttribution=)]

相关资讯

防患未然!基因检测帮助预测癌症风险

癌症,一直是健康领域的一个热点问题。随着人们认识的提高,许多人对癌症的了解也都不断加深。例如诱发癌症的因素有很多,例如抽烟、酗酒等等都会极大程度增加人们患上癌症的风险。 然而,很少有人意识到,基因也是导致癌症的重要因素之一。例如一个名为BRCA的基因一旦出现突变,携带次突变型的女性患上乳腺癌的风险将骤增80%。研究显示,这一基因一旦突变会阻碍DNA的自我修复,从而提高正常细胞癌变的几率。类似的研

AEMB:红酒或可抑制癌症的发生

饮酒是引发头颈癌的主要风险因子,但是近日发表在国际杂志Advances in Experimental Medicine and Biology上的一篇研究论文中,来自科罗拉多大学癌症研究中心的研究者表示,在葡萄皮和红酒中发现的化学物质白藜芦醇或可有效抑制癌症的发生。研究者Robert Sclafani表示,白藜芦醇可以攻击那些DNA损伤未修复的细胞,使其致死进而抑制癌症的发生,酒精可以损伤细胞,

JCO:美国肿瘤科医生对于癌症患者使用草药和补品的知识、态度和实践的全国性调查

背景:补充和替代疗法在肿瘤患者中的使用越来越多,其中具有生物活性的草药和补品(herbs and supplements,HS)会与化疗药物相互作用甚或增加治疗的毒副作用,所以医生有义务了解HS方面的知识以指导患者正确使用。而目前,关于医生是否与患者讨论HS的使用及如何进行讨论还不清楚。为了解美国肿瘤科医生对于患者使用HS的知识、态度及实践行为,美国德克萨斯大学MD安德森癌症中心(Universi

Nature:5篇论文关注个体化癌症疗法

为了开发出个体化的癌症疗法,越来越多的研究人员致力于调查个体对癌症产生的免疫反应,以寻找为患者量身定制治疗的途经。 伴随着这一转变而来是一类新疗法的出现,其旨在解除免疫系统的束缚,使之能够对癌细胞发动攻击。发表在11月27日《自然》(Nature)杂志上的5项新研究将焦点转向了免疫系统,来调查哪些患者有可能会对抑制PD-1蛋白活性的癌症药物产生反应,以及肿瘤触发免疫反应的机制。这种方法

JCO:癌症患者体重减轻等级的诊断标准

目的:现有关于癌症患者具有临床意义的体重减轻(Weight Loss,WL)的定义各异,尚无定论,而且没有考虑到人口趋于肥胖的现状。方法:收集了来自加拿大和欧洲的8160名癌症患者基于人群的数据,包括体质指数(Body Mass Index,BMI)、WL比例(%WL),并一直追踪到患者死亡。所收集的数据纳入多元分析,其中年龄、性别、癌症部位、癌症分期及体力状态作为控制变量。分析了BMI、%WL与

国际癌症研究中心:常见I类致癌物质清单

先放最权威的干货:IARC - INTERNATIONAL AGENCY FOR RESEARCH ON CANCER 这个是WHO下属的国际癌症研究中心的网站,里面能找到相当权威的致癌物信息 一般大家常见的该机构对于致癌物的评级是基于证据强度的,分为I级(group 1, 对人类致癌,有充分的证据证明对人类有致癌作用)、II级(group 2,对人类很可能致癌的IIA级和对人类可